GH-secretagogue family: Ipamorelin, Hexarelin, GHRP-2, GHRP-6 compared structurally

Why a structural comparison and not an outcome comparison

The four canonical short GH-secretagogue peptides — Ipamorelin, Hexarelin, GHRP-2, GHRP-6 — sit close together in commercial shorthand and a long way apart in chemistry. Sequence length, residue substitutions, terminal capping, and ghrelin-receptor binding-pocket engagement all differ in ways that affect chromatographic retention, mass-spec identity, and assay-window characterisation. This article compares them at the structural and analytical level appropriate to in-vitro reference-standard work, not at the outcome level — which is the framing competitors use and the framing we cannot follow. [1]

The shared design constraint: GHSR-1a binding-pocket complementarity

All four molecules are short hexapeptides or pentapeptides designed as ligands of the growth hormone secretagogue receptor type 1a (GHSR-1a). The receptor pocket has a defined geometry that a productive ligand needs to match: a hydrophobic cavity around the position-2 residue with strong preference for D-stereochemistry, a basic-residue contact at the C-terminus, and a critical aromatic stacking interaction at one of the central positions. The four peptides differ in how they meet these constraints, and the differences show up directly on the COA spec sheet. [2]

A 5-residue versus 6-residue chain matters less than the position-2 substitution and the C-terminal cap. Ipamorelin uses an α-aminoisobutyric acid (Aib) at the N-terminus to resist N-terminal proteolysis; GHRP-2 uses a D-Ala at position 1; Hexarelin and GHRP-6 retain a free His at the N-terminus. The position-2 residue varies more dramatically: Ipamorelin uses D-2-naphthylalanine, GHRP-2 uses D-2-naphthylalanine, GHRP-6 uses D-tryptophan, Hexarelin uses D-2-methyl-tryptophan. Those substitutions are the structural fingerprint. [3]

Ipamorelin — the pentapeptide

<a href="/product/cp-012">Ipamorelin</a> is the shortest of the four — a synthetic pentapeptide with the sequence Aib-His-D-2-Naphthyl-Ala-D-Phe-Lys-NH₂. The molecular weight is 711.9 Da. The α-aminoisobutyric acid at position 1 is the canonical N-terminal stabilising residue; the C-terminal lysine carries the basic-residue contact for the receptor pocket; and the D-naphthylalanine at position 3 (relative to Aib) and D-phenylalanine at position 4 provide the hydrophobic core that fits the GHSR-1a pocket. [4]

Analytical implications: the relatively short length means a clean chromatogram on a standard C18 gradient, with the main peak well-separated from deletion-sequence impurities. The mass-spec identity check at 711.9 Da is unambiguous. The C-terminal amide is critical — an acid-form impurity would read at 712.9 Da on HPLC-MS (+1 Da from loss of NH₂, gain of OH), easily distinguished from the main peak. Karl Fischer water content typically lands 3-5% for this peptide; the residue composition does not retain bound water aggressively. [5]

Ipamorelin's selectivity profile within the GH-secretagogue family is one of the operational reasons it appears in many in-vitro characterisation programmes as the reference comparator. Unlike GHRP-6 and Hexarelin, which engage additional receptor families beyond GHSR-1a, Ipamorelin shows narrower cross-reactivity in published in-vitro binding-curve data. For chromatographic-comparator runs, this analytical narrowness means a cleaner background — fewer secondary binding events to confound the primary readout. The lyophilized 5 mg vial of <a href="/product/cp-012">CP-012 Ipamorelin</a> is supplied with a Certificate of Analysis stating HPLC purity (typically ≥99%), HPLC-MS identity at 711.9 ±0.5 Da, water content by Karl Fischer (typically 3-4%), and residual solvents against ICH Q3C(R8). The lot-reservation workflow is available for multi-shipment characterisation programmes that need within-batch consistency. [6]

Hexarelin — the methylated tryptophan variant

<a href="/product/cp-013">Hexarelin</a> is a hexapeptide with the sequence His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂. The molecular weight is 887.1 Da. The defining structural feature is the D-2-methyl-tryptophan at position 2 — the methyl group on the indole ring confers resistance to enzymatic oxidation that the canonical D-tryptophan (used in GHRP-6) cannot offer. The position-4 tryptophan is the second aromatic residue; the C-terminal D-Phe-Lys-NH₂ motif matches the receptor-pocket contact found in Ipamorelin, GHRP-2, and GHRP-6. [7]

Analytical implications: two tryptophan residues mean the molecule absorbs strongly at both 220 nm (peptide bond) and 280 nm (indole). The two-wavelength dual-readout is occasionally useful for distinguishing Hexarelin lots from analogues without aromatic content. Mass-spec identity at 887.1 Da; tryptophan oxidation impurities read at +16 Da (kynurenine variant) or +32 Da (di-oxidation). The 2-methyl-Trp residue is itself an analytical marker because the methyl group's mass contribution (+14 Da vs canonical D-Trp) distinguishes Hexarelin from a hypothetical impurity that lacks the methylation. For lots that have been stored under sub-optimal conditions (warmer than -20 °C, exposed to light, or unsealed during handling), the +16 Da kynurenine variant fraction is the first impurity-profile metric to check on the receiving-sample HPLC trace. [8]

GHRP-2 (pralmorelin) — the D-Ala variant

<a href="/product/cp-014">GHRP-2</a>, also known as pralmorelin, is a hexapeptide with the sequence D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH₂. The molecular weight is 817.9 Da. The N-terminal D-Ala replaces the histidine seen in Hexarelin/GHRP-6, removing the basic imidazole side chain at the N-terminus. The D-2-naphthylalanine at position 2 matches the Ipamorelin position-3 design — these two peptides share that hydrophobic pocket-binding residue despite differing in length and other positions.

Analytical implications: a single tryptophan residue (position 4) provides A280 absorbance. Mass-spec identity at 817.9 Da. The naphthylalanine residue is detectable on HPLC by its characteristic late-elution behaviour (more hydrophobic than tryptophan); a deletion-sequence impurity missing the naphthylalanine would shift the main peak earlier and the mass to 627.7 Da, easily distinguished. Position-1 D-Ala is harder to verify analytically because L-Ala has identical mass — chiral HPLC or chiral derivatisation is needed if D-stereochemistry verification is the specific analytical question.

GHRP-6 — the canonical reference

<a href="/product/cp-015">GHRP-6</a> is the original member of the family, described by Bowers and colleagues in the 1980s. Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂; molecular weight 872 Da. The N-terminal histidine, D-tryptophan at position 2, and dual tryptophan content (positions 2 and 4) make this the most aromatic-rich molecule in the family. The structural framework served as the template against which Hexarelin (with the position-2 methyl-Trp substitution) and GHRP-2 (with the position-1 D-Ala substitution and position-2 D-Nal substitution) were designed.

Analytical implications: two tryptophans give strong A280 signal. Mass-spec identity at 872 Da. The position-2 D-Trp is oxidation-sensitive; the +16 Da kynurenine impurity is the most common storage-related impurity-profile signature. A storage-aged GHRP-6 lot will accumulate Trp oxidation faster than Hexarelin (where the methyl group provides some protection) — for long-term reference-standard storage, the lot should be sealed under inert atmosphere and protected from light, conditions Canada Peptides applies to every released vial.

The structural fingerprint table

Side-by-side, the four peptides resolve cleanly along three structural axes — length, position-2 residue, and N-terminal cap. This is the analytical reference frame that matters when comparing COAs across the family:

• <strong>Ipamorelin</strong> (5 residues, 711.9 Da): Aib-His-D-Nal-D-Phe-Lys-NH₂ · N-terminal Aib · single naphthyl aromatic

• <strong>Hexarelin</strong> (6 residues, 887.1 Da): His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH₂ · N-terminal His · methylated Trp + Trp · two aromatic residues

• <strong>GHRP-2</strong> (6 residues, 817.9 Da): D-Ala-D-Nal-Ala-Trp-D-Phe-Lys-NH₂ · N-terminal D-Ala · naphthyl + Trp aromatic combination

• <strong>GHRP-6</strong> (6 residues, 872 Da): His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ · N-terminal His · dual Trp · most aromatic-rich

• All four share the C-terminal D-Phe-Lys-NH₂ motif — the basic-residue contact + the hydrophobic D-Phe stacking interaction

What this means for the COA reviewer

A procurement lead comparing release records across the family should read five COA lines side-by-side. First, sequence string — explicit notation with D-stereochemistry markers (D-Nal, D-Trp, D-2-Me-Trp), naphthyl-vs-tryptophan distinction at the position-2-or-3 hydrophobic residue, and N-terminal cap (Aib vs His vs D-Ala). Second, molecular weight — the four masses (711.9 / 887.1 / 817.9 / 872) are distinctive enough that a single misread number is hard to miss. Third, HPLC purity by reversed-phase HPLC at 220 nm against lot-specific integration. Fourth, HPLC-MS identity within ±0.5 Da; for tryptophan-containing peptides, the impurity profile should resolve the +16 Da oxidation variant separately. Fifth, Karl Fischer water content; this family typically lands 3-5%.

For a deeper structural-comparison framework, the article on <a href="/research-guide/bpc-157-vs-tb-500-structural">BPC-157 vs TB-500 structural comparison</a> applies the same five-line discipline to a different peptide family. For the related GHRH-secretagogue family — Sermorelin, Tesamorelin, CJC-1295 with and without DAC — see the article on <a href="/research-guide/cjc-1295-dac-vs-no-dac-structure">CJC-1295 DAC vs No-DAC structural difference</a>, which complements this short-peptide family with the longer GHRH-analogue branch.

The non-peptide alternative in this category is <a href="/product/cp-016">MK-677 (Ibutamoren)</a> — a small-molecule GHSR-1a agonist with a spiro-piperidine scaffold rather than a peptide backbone. MK-677 is not part of the structural comparison above because its chemistry is fundamentally different, but it serves the same receptor pocket and appears in many of the same in-vitro characterisation workflows as a non-peptide comparator.

Storage and reconstitution notes specific to this family

All four peptides are supplied as lyophilized peptide reference standards in butyl-stoppered, crimp-sealed Type-I borosilicate vials under inert atmosphere. The shared storage condition is sealed at -20 °C, protected from light, with bacteriostatic water (0.9% benzyl alcohol) as the typical reconstitution solvent. The article on <a href="/research-guide/dmso-vs-bac-water-reconstitution">DMSO vs bacteriostatic water for peptide reconstitution</a> covers the solvent-choice decision in more detail; for this family, water-solubility is good across all four molecules and DMSO is rarely needed.

Tryptophan-containing members of the family (GHRP-6, GHRP-2, Hexarelin) benefit from working-stock storage under inert atmosphere (nitrogen-purged tubes) or with an trace antioxidant addition if the stability programme is multi-week. Ipamorelin, lacking tryptophan, does not require the same antioxidant protection. The article on <a href="/research-guide/peptide-aliquotting-best-practices">peptide aliquotting best practices</a> covers the one-freeze-one-thaw discipline that applies across all four molecules.

Summary

• Four short GH-secretagogue peptides — Ipamorelin (711.9 Da, 5 residues), Hexarelin (887.1 Da, 6 residues), GHRP-2 (817.9 Da, 6 residues), GHRP-6 (872 Da, 6 residues) — share the C-terminal D-Phe-Lys-NH₂ motif but differ at the N-terminal cap and the position-2 hydrophobic residue.

• Position-2 residue is the structural fingerprint: D-Nal (Ipamorelin, GHRP-2), D-Trp (GHRP-6), D-2-methyl-Trp (Hexarelin).

• Tryptophan-containing members (GHRP-6, GHRP-2, Hexarelin) are oxidation-sensitive; +16 Da kynurenine impurity is the load-bearing impurity-profile line.

• MK-677 is the non-peptide small-molecule alternative for the same receptor pocket — different chemistry, same in-vitro use case as a comparator.

FAQ

What's the fastest way to distinguish Ipamorelin from GHRP-2 on a COA?

Sequence length and molecular weight. Ipamorelin is a 5-residue pentapeptide at 711.9 Da; GHRP-2 is a 6-residue hexapeptide at 817.9 Da. The 106 Da mass difference is well beyond release-test tolerance and resolves cleanly on HPLC-MS.

How are Hexarelin and GHRP-6 different structurally?

Both are hexapeptides with the same N-terminal His and the same C-terminal D-Phe-Lys-NH₂ motif. The difference is the position-2 residue: Hexarelin uses D-2-methyl-Trp (adds a methyl group to the indole, providing oxidation resistance), GHRP-6 uses the canonical D-Trp. Mass difference is 14 Da (Hexarelin 887.1 vs GHRP-6 872).

Why does the impurity profile matter more for tryptophan-containing GH-secretagogues?

Tryptophan is oxidation-sensitive. The kynurenine variant (+16 Da on the indole ring oxidation) and di-oxidation variant (+32 Da) accumulate over storage exposure to oxygen and light. The release COA should report any +16 Da or +32 Da impurity as a separate spec line; storage-aged working stocks should be re-characterised by HPLC at the end of the planned bench window.

Is MK-677 part of this family?

Functionally yes — MK-677 (ibutamoren) is a GHSR-1a agonist used as a comparator standard in the same in-vitro receptor-binding and signalling research as the four peptides. Structurally no — MK-677 is a non-peptide small molecule with a spiro-piperidine scaffold, not a peptide. It appears in many of the same characterisation workflows but the COA review framework differs.

Are these four peptides interchangeable on a chromatographic column?

Not quite. The shared D-Phe-Lys-NH₂ C-terminus gives broadly similar retention behaviour, but the position-2 residue (D-Nal vs D-Trp vs D-2-Me-Trp) shifts retention enough to separate the four cleanly on most C18 gradients. A 30-minute gradient at 220 nm typically resolves all four as distinct peaks; a 60-minute gradient resolves them with more space between, including their impurity profiles.

Frequently asked questions

References

1. Kojima M., Hosoda H., Date Y. et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. · DOI
2. Howard A., Feighner S., Cully D. et al. (1996). A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release. Science. · DOI
3. Ionescu M., Frohman L. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology &amp; Metabolism. · DOI
4. Henninge J., Pepaj M., Hullstein I. et al. (2010). Identification of CJC‐1295, a growth‐hormone‐releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. · DOI
5. Timms M., Ganio K., Forbes G. et al. (2018). An immuno polymerase chain reaction screen for the detection of CJC‐1295 and other growth‐hormone‐releasing hormone analogs in equine plasma. Drug Testing and Analysis. · DOI
6. Merrifield R. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society. · DOI
7. FIELDS G., NOBLE R. (1990). Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research. · DOI
8. Whitelegge J. (n.d.). HPLC and Mass Spectrometry of Intrinsic Membrane Proteins. HPLC of Peptides and Proteins. · DOI